Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age

Zhe Shen1, Stefan Munker2, Fugang Luo3, Han Ma1, Chaohui Yu1, Youming Li1 *

1 Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003, Hangzhou, China, 2 Molecular Hepatology-Alcohol Associated Diseases, II. Medical Clinic Faculty of Medicine at Mannheim, University of Heidelberg, 68167, Mannheim, Germany, 3 College of Medicine, Zhejiang University, 310058, Hangzhou, China

Abstract

There is a gap between the association of non-alcoholic fatty liver disease (NAFLD) and renal function in an apparently healthy population. This study aims to assess whether NAFLD is associated with estimated glomerular filtration rate (eGFR) levels and to understand early changes of eGFR in NAFLD. A cross-sectional study was performed among apparently healthy persons who underwent general health screening including laboratory assessments and hepatic ultrasonography from January 2013 to December 2013 at the First Affiliated Hospital of Zhejiang University, College of Medicine, China. This study included 1,193 subjects with a mean age of 48 years. Prevalence of NAFLD was 31.3%. Mean eGFR was significantly lower in NAFLD than in controls (107 ± 19 mL/min/1.73 m² vs. 113 ± 23 mL/min/1.73 m², P<0.001). Correlation analysis between eGFR and NAFLD related risk factors revealed an inverse correlation between eGFR levels and some NAFLD risk factors (all P<0.01). All subjects were classified into five phases according to age. Average eGFR levels of NAFLD were lower than controls in three phases for subjects with ≤50 years of age (all P<0.05), while there were no significant differences on average eGFR levels between NAFLD and controls in two phases for subjects with >50 years of age (Both P>0.05). The eGFR level is significantly associated with NAFLD and its risk factors in an apparently healthy population. Effects of NAFLD on eGFR could be dependent on age.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. Development of this disease is closely associated with obesity, type 2 diabetes mellitus, dyslipidemia and hypertension; which form a cluster of metabolic disorders that is now identified as a metabolic syndrome [1,2]. Increasing evidence suggests that obesity, diabetes, dyslipidemia and hypertension are all well-known risk factors for chronic kidney disease (CKD) [3–6]. Growing experimental and epidemiological evidence indicates that NAFLD and CKD could...
share common pathogenic mechanisms and interactions [7–12]. Thus, the association between NAFLD and CKD has become a hot research issue. Moreover, a link between NAFLD and CKD has been shown to be certain in a systematic review and meta-analysis [13].

Mechanisms of NAFLD in developing CKD remains unclear, and disturbances in the renin-angiotensin-aldosterone system could be a risk factor for kidney disease in NAFLD [14]. Whether NAFLD could influence renal function in the early phase or before NAFLD develops CKD remains to be answered. There is a gap between the association of NAFLD and renal function in apparently healthy persons with normal estimated glomerular filtration rate (eGFR) levels and nonhypertensive/nondiabetic diseases. Verifying the influence of NAFLD in kidneys in the early phase would enable us to further understand the relationship of NAFLD and CKD. This study aims to assess whether NAFLD is associated with eGFR levels and to understand the early changes of eGFR in NAFLD.

Materials and Methods

Study design and subjects

From January 2013 to December 2013, a population of subjects who underwent health screening including physical examination, laboratory assessments and hepatic ultrasonography at the International Health Care Center, the First Affiliated Hospital of Zhejiang University, College of Medicine, China was evaluated in this study. The style of this annual health screening was the same as a previous study [15], but they were different years of health screening. All subjects voluntarily participated in this study. Subjects with the following criteria were excluded: (i) subjects who drunk excessive alcohol (alcohol consumption per week ≥140 g for men or ≥70 g for women); (ii) subjects who were taking antihypertensive, antidiabetic, lipid-lowering or hypouricemic agents; (iii) subjects with a history of chronic viral hepatitis, autoimmune hepatitis, schistosomiasis japonica, drug-induced liver disease or kidney disease. Finally, a total of 1,193 eligible subjects were enrolled in this study (736 men with a mean age of 48.3 ± 8.4 years and 457 women with a mean age of 47.3 ± 8.4 years). All procedures were approved by the Ethics Committee of the College of Medicine of Zhejiang University. Before the study, each method and its potential risks were explained in detail to each participant, and written informed consent were obtained.

Physical examination

All subjects were required to fast overnight and invited to have a physical examination in the next morning. After a health habit inventory was recorded, body measurement and blood pressure were performed by a trained physician. Then, body mass index (BMI) was calculated as mass (kg)/height (m2). Waist circumference (WC) was measured with a measuring tape, which was positioned midway between the lowest rib and superior border of the iliac crest as the subject exhaled normally. Three blood pressure measurements were taken with an automated sphygmomanometer on the right arm at a comfortable sitting position after a five-minute rest. The second and third pressure readings were averaged. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded and used for analysis.

Laboratory assessments

Peripheral venous blood samples were collected after physical examination and used for the analysis of biochemical values. All serum biochemistries were measured by a Hitachi 7600–110 automatic analyzer (Hitachi Co., Tokyo, Japan). Values included γ-glutamyltransferase (GGT), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDLc),
low-density lipoprotein (LDLc), very low density lipoprotein cholesterol (VLDLc), serum urine acid (SUA), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and serum creatinine (Scr). Kidney function level was defined by eGFR, which was evaluated by the formula developed and validated in the Modification of Diet in Renal Disease (MDRD) study [16]. The MDRD formula is as follows: eGFR = 186 x SCr-1.154 x age-0.203 x 1.233 (Chinese) x 0.742 (if female).

Ultrasonographic examination

Hepatic ultrasonography for all subjects was performed by trained ultrasonographists. Ultrasonographic criteria of hepatic steatosis included liver and kidney echo discrepancy, presence of increased liver echogenicity (bright), echo penetration into the deep portion of the liver, and clarity of liver blood vessel structures [17–19].

Statistical analysis

Statistical analysis was performed with SPSS 13.0 statistical package (SPSS Inc., Chicago, Illinois, USA). Kolmogorov–Smirnov test was used to assess whether continuous data were normally distributed. Continuous variables are presented as mean and standard deviation or median and interquartile range (IQR) as appropriate. Continuous data for different groups were compared using the Student t-test or Mann–Whitney U-test. Chi-square (χ²) test was used for comparisons of categorical variables. Pearson’s or Spearman’s analysis was used to determine correlations between parameters. P<0.05 was considered statistically significant.

Results

Subject characteristics

Among the 1,193 included subjects, 373 (31.3%) were diagnosed as NAFLD, and 820 (68.7%) were diagnosed as non-NAFLD. Subject characteristics by NAFLD status are illustrated in Table 1. There was no significant difference on average age between subjects with NAFLD and subjects without NAFLD. Male population, as well as SBP, DBP, BMI, WC, GGT, TG, TC, LDLc, VLDLc, SUA, FPG and HbA1c levels, were significantly higher in the NAFLD group, compared to the control group (All P<0.01). Meanwhile, HDLc and eGFR levels were significantly lower in subjects with NAFLD when compared to controls (All P<0.01).

Association between eGFR levels and NAFLD related risk factors

Correlation analysis between eGFR and NAFLD related risk factors revealed an inverse correlation between eGFR levels and some NAFLD risk factors [DBP (r = -0.076, P<0.01), BMI (r = -0.156, P<0.001), WC (r = -0.204, P<0.001), GGT (r = -0.157, P<0.001), TG (r = -0.183, P<0.001), TC (r = -0.123, P<0.001), LDLc (r = -0.125, P<0.001), VLDLc (r = -0.125, P<0.001), SUA (r = -0.355, P<0.001), HbA1c (r = -0.082, P<0.01), and HDLc (r = 0.091, P<0.01)]. There was no significant correlation between eGFR levels and SBP, and same results were observed between eGFR levels and FPG (Both P>0.05, Table 2).

Association of eGFR levels and NAFLD in different ages

To investigate the relationship between eGFR levels and NAFLD in different ages, all subjects were classified into five phases according to age: phase one (P1), age ≤40 years; phase two (P2), age 41–45 years; phase three (P3), age 46–50 years; phase four (P4), age 51–55 years; phase five (P5), age >55 years. Average eGFR levels of subjects with and without NAFLD were analyzed.
As shown in Table 3, average eGFR levels of subjects with NAFLD was lower than subjects without NAFLD in phase one, two and three (All $P < 0.05$). However, there was no significant difference on average eGFR levels between NAFLD and non-NAFLD in phase four and five (Both $P > 0.05$).

As shown in Fig 1, there were significant differences on average eGFR levels between NAFLD and non-NAFLD in the previous three phases of the five phases (All $P < 0.05$). Moreover, there was no significant difference on the average eGFR level of NAFLD among the three phases ($P > 0.05$). However, there was a significant difference on the average eGFR level of NAFLD between the previous three phases and the later two phases ($P < 0.05$).

### Discussion

NAFLD is one of the most common chronic liver diseases, which is closely associated with metabolic syndrome; and its individual components include elevated blood pressure, dyslipidemia,
high plasma glucose, obesity, and so on [2,20]. Renal dysfunction and injury is also a common health problem in modern society; and similar to NAFLD, CKD has also been linked to metabolic syndrome and its individual components [21,22]. Therefore, the link between NAFLD and CKD has been pushed to the forefront of research. A meta-analysis on the association of NAFLD and CKD has been conducted to determine whether the presence and severity of NAFLD is associated with the increased risk and severity of CKD. In our study, we further clarified the influence of NAFLD to kidney function in the early phase.

| Age (year) | No. of subjects | eGFR (mL/min/1.73 m2) | T value | P value |
|------------|----------------|-----------------------|---------|---------|
| ≤40        | With NAFLD (n) 86 | 108.6 ± 19.2           | 4.159   | 0.000   |
|            | Without NAFLD (n) 226 | 122.0 ± 27.4          |         |         |
| 41–45      | With NAFLD (n) 85 | 108.6 ± 20.3           | 2.717   | 0.007   |
|            | Without NAFLD (n) 171 | 116.0 ± 20.1          |         |         |
| 46–50      | With NAFLD (n) 72 | 108.9 ± 19.4           | 2.095   | 0.037   |
|            | Without NAFLD (n) 125 | 117.8 ± 21.0          |         |         |
| 51–55      | With NAFLD (n) 99 | 103.3 ± 17.9           | 1.135   | 0.257   |
|            | Without NAFLD (n) 210 | 108.9 ± 18.5          |         |         |
| ≥55        | With NAFLD (n) 64 | 101.9 ± 17.1           | 0.354   | 0.724   |
|            | Without NAFLD (n) 148 | 102.9 ± 20.5          |         |         |

doi:10.1371/journal.pone.0130614.t003
In this study, the comparison of variables between NAFLD and non-NAFLD subjects revealed a significant difference on average eGFR level, except for other well-known variables in an apparently healthy population. Targher G et al believed that fatty and inflamed liver produces pro-inflammatory factors which can further worsen kidney function [23]. Machado MV et al found that the presence and severity of liver inflammation correlated linearly with lower eGFR in their study [24].

Additionally, our data revealed that eGFR was significantly associated with most NAFLD risk factors including blood pressure, obesity parameters, liver enzyme, lipid level, uric acid, and HbA1c. A seven-year prospective cohort study performed by Wang Q et al. revealed a dose-response relationship between baseline blood pressure and eGFR level decline [25]. Kalaitzidis RG et al. believed that obesity was associated with increased risk of CKD and that a direct relationship exists between BMI and CKD risk. Moreover, central obesity measurements such as waist circumference could be a better predictor of CKD progression and mortality [14]. A US general population survey from 2001 to 2006 revealed a strong and independent relationship of increased serum GGT concentrations with CKD [26]. Hou X et al. thought that TC and TG were closely associated with mildly reduced eGFR levels in subjects with normal serum lipid levels [27]. A cohort study by Chou YC et al. revealed that elevated SUA levels independently predicted the risk of new-onset CKD [28]. A longitudinal observational study by Yokoyama H et al. demonstrated that a higher HbA1c baseline resulted in a more rapid GFR decline [29]. These studies suggest that NAFLD may not only be associated with renal dysfunction, but also be actively involved in its pathogenesis. There may be several explanations on the effects of NAFLD on eGFR levels such as disturbed tumor necrosis factor system, imbalance of renin-angiotensin-aldosterone system, insulin resistance, and chronic inflammation [14,23,30,31]. However, underlying mechanisms between the association of NAFLD and renal dysfunction remains unclear.

Age is an important risk factor for kidney disease; and eGFR is calculated by age, which is one of the important parameters. Thus, the older the age, the more the decline in eGFR level is affected. Additionally, age was also strongly associated with the development and progression of NAFLD [32]. Our data revealed that average eGFR levels of subjects with NAFLD was lower than controls when age was lower than 50 years, while there was no significant difference on average eGFR level between NAFLD and controls when age was more than 50 years. The fact that differences vanished after the age of 50, suggests that probably the importance the common risk factors for NAFLD and diminished eGFR is lost after a certain age. Certainly, the certain age needs to be confirmed in a follow-up study.

Nevertheless, there was a certain limitation in our study. Firstly, this study did not provide information on NAFLD disease severity due to lack of hepatic pathology, it was not able to understand the relationship between inflammation levels and eGFR levels. Secondly, this study only performed a cross-sectional analysis, and was not able to provide a cause and effect link or determine the underlying mechanism. In summary, our results revealed that eGFR levels significantly decreased in NAFLD compared to the control group, eGFR levels were significantly associated with related variables of NAFLD, and the effect of NAFLD on eGFR could be dependent on age. Certainly, further studies are needed to understand the potential mechanism of the association between NAFLD and eGFR levels through animal experiments and follow-up studies.

**Acknowledgments**

We gratefully acknowledge the assistance of the interviewers, physical examination physicians, ultrasonographists, and computer assistants for this study.
Author Contributions
Conceived and designed the experiments: YL. Performed the experiments: ZS FL HM CY. Analyzed the data: ZS SM. Contributed reagents/materials/analysis tools: ZS. Wrote the paper: ZS SM.

References
1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923. PMID:12668987
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850. PMID:11473047
3. Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al. (2008) Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 52:39–48. doi:10.1053/j.ajkd.2008.03.003 PMID:18440684
4. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. (2007) The epidemiology of obesity. Gastroenterology 132:2087–2102. PMID:17498505
5. Prasad GV. (2014) Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol 3:210–219. doi: 10.5527/wjn.v3.i4.210 PMID:25374814
6. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047. PMID:17986697
7. Hribal ML, Procopio T, Petta S, Sciacqua A, Grimaudo S, Pipitone RM, et al. (2013) Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with non-alcoholic fatty liver disease. J Clin Endocrinol Metab 98:E304–E308. doi:10.1210/jc.2012-3290 PMID:23316084
8. Kamenický P, Mazzetti G, Lombè M, Giustina A, Chanson P. (2014) Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35:234–281. doi: 10.1210/er.2013-1071 PMID:24423979
9. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y, et al. (2011) Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 60:735–739. doi:10.1016/j.metabol.2010.07.022 PMID:20817213
10. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. (2014) Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 11:e1001680. doi:10.1371/journal.pmed.1001680 PMID:25050550
11. Kalaitzidis RG, Siamopoulos KC. (2011) The role of obesity in kidney disease: recent findings and potential mechanisms. Int Urol Nephrol 43:771–784. doi:10.1007/s11255-011-9974-1 PMID:21544651
12. Shen Z, Qin Y, Liu Y, Lu Y, Munker S, Chen L, et al. (2013) Helicobacter pylori infection is associated with the presence of thyroid nodules in the euthyroid population. PLoS One 8:e80042. doi:10.1371/journal.pone.0080042 PMID:24246004
13. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147. PMID:12859163
14. Lonardo A, Bellini M, Tartoni P, Tondelli E. (1997) The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 29:351–356. PMID:9476190
15. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. (1991) Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43:36–31. PMID:19999669
16. Mezin M, Pereira WC, Abdelwahab A, Degott C, Laugier P. (2005) In vitro chronic hepatic disease characterization with a multiparametric ultrasonic approach. Ultraso 43:305–313. PMID:15737980
20. Stefan N, Kantartzis K, Haring HU. (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960. doi: 10.1210/er.2008-0009 PMID: 18723451

21. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167–174. PMID: 14757614

22. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. (2004) Predictors of new-onset kidney disease in a community-based population. JAMA 291:844–850. PMID: 14970063

23. Targher G, Marra F, Marchesini G. (2008) Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51:1947–1953. doi: 10.1007/s00125-008-1135-4 PMID: 18762907

24. Machado MV, Gonçalves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. (2012) Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 32:241–248. doi: 10.1111/j.1478-3231.2011.02623.x PMID: 22098270

25. Wang Q, Xie D, Xu X, Qin X, Tang G, Wang B, et al. (2015) Blood pressure and renal function decline: a 7-year prospective cohort study in middle-aged rural Chinese men and women. J Hypertens 33:136–143. doi: 10.1097/HJH.0000000000000360 PMID: 25255396

26. Targher G, Kendrick J, Smits G, Chonchol M. (2010) Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Nutr Metab Cardiovasc Dis 20:583–590. doi: 10.1016/j.numecd.2009.05.012 PMID: 19699624

27. Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. (2014) Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS One 9:e106778. doi: 10.1371/journal.pone.0106778 PMID: 25275610

28. Chou YC, Kuan JC, Yang T, Chou WY, Hsieh PC, Bai CH, et al. (2014) Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol 2014 Nov 20. [Epub ahead of print]

29. Yokoyama H, Kanno S, Takahashi S, Yamada D, Itoh H, Saito K, et al. (2009) Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol 4:1432–1440. doi: 10.2215/CJN.06511208 PMID: 19713288

30. Carbone F, Montecucco F, Mach F, Pontremoli R, Viazzi F. (2013) The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thromb Haemost 110:940–958. doi: 10.1160/TH13-06-0499 PMID: 23966104

31. Sarafidis PA, Ruilope LM. (2006) Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 26: 232–244. PMID: 16733348

32. Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, et al. (2014) Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol Res 2014 Jun 30. [Epub ahead of print]